Clinical Trial Detail

NCT ID NCT02974725
Title A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

melanoma

lung non-small cell carcinoma

Therapies

LXH 254 + Ribociclib

LXH 254 + Trametinib

LTT462 + LXH 254

Age Groups: adult senior

Additional content available in CKB BOOST